S2Medical

🚀 Epiprotect Sales Set to Triple in 2024!

We’re excited to share that Epiprotect, developed by S2Medical and powered by our strategic partner, is projected to achieve triple sales growth in 2024, with secured revenue already exceeding SEK 9 million!

Starting in 2024, our royalty model— 2% of sales revenue and 10% of net profit —provides a stable foundation for long-term growth in the multi-billion-dollar wound care market.

This success accelerates the commercialisation of our other innovative solutions:
AMP technologies – antimicrobial peptides
IvaQ – advanced negative pressure wound therapy
Instagraft – efficient skin grafting

Through our partner’s global network, we’re expanding into new markets and strengthening our leadership in wound care. Stay tuned for more updates as we continue to transform healthcare!

For more information, visit our website:
www.s2m.se

The Wound Healing Company

We have initiated the commercialization of a new cosmetic formulation based on research into antimicrobial peptides (AMP) and skin health. We are also applying for INCI listing, expected to take around six months, and plans to develop and launch skincare products shortly after.

In collaboration with Eyracure AB, S2Medical will focus on product development, manufacturing, and commercialization.
This partnership aims to capitalize on both companies' strengths to bring innovative skincare solutions to the market quickly.

With the global cosmetics market valued at USD 300-500 billion, we see great potential to establish ourselves with scientifically-backed products.

This initiative aligns with the company's growth strategy, which is supported by its ongoing rights issue and the acquisition of Eyracure AB.

For more information, visit our website:

The Wound Healing Company

We are pleased to share that the South African patent authorities have granted a patent for BioLAP-20, an innovative molecule developed by Eyracure AB, a company in which S2Medical is a part-owner.
BioLAP-20 is designed to repair hair by permanently linking damages when activated by specific light wavelengths, marking a significant advancement in hair care.

This patent secures Eyracure’s intellectual property in South Africa, a rapidly growing market for premium cosmetics. In partnership with Lyko, Scandinavia's leading beauty distributor, we are well-positioned to bring BioLAP-20 to market and drive growth in both existing and new markets.

For more information, visit our website:
www.s2m.se

The Wound Healing Company

Exciting News from S2Medical! 🥳🥳

We're thrilled to announce that an independent study published in the *Journal of Plastic, Reconstructive & Aesthetic Surgery* has shown outstanding results for our product, Epiprotect®. Conducted at Stoke Mandeville Hospital, the study involved 99 pediatric patients (ages 0-18) treated for partial-thickness burns.

Key Findings:
- Epiprotect® provides significant pain relief, safety, and quick and easy follow-ups.
- It demonstrates comparable acute healing outcomes to Biobrane® from Smith & Nephew.
- Most notably, Epiprotect® has a significantly lower infection rate (2.6%) compared to Biobrane® (16.4%).

Our CEO, Petter Sivlér, emphasizes, "The reduction in infection risks with Epiprotect® is an enormously important finding, especially since infections in children can mean the difference between life and death."

We expect these results will accelerate the commercialization of Epiprotect®, leading to increased royalty revenues and further opportunities for expansion.

Stay tuned for more updates as we continue to make strides in pediatric burn healing!

For more information, visit our website:

The Wound Healing Company

We are thrilled to announce that S2Medical AB (publ) is now debt-free after successfully settling all our obligations to creditors.
This milestone marks a significant step forward, confirming the successful implementation of our corporate restructuring measures.

"This achievement is a testament to our resilience and ability to overcome challenges. We've laid a solid foundation for a stable and sustainable future by fulfilling our obligations.
We thank our shareholders and creditors for their unwavering support and trust throughout this process.
We're excited about a bright future where we can focus on increasing sales and continuing to develop and expand our innovative product portfolio.
Special thanks to ABENA, our global partner in healing chronic wounds and burns," says Petter Sivlér, CEO of S2Medical AB (publ).

Onwards and upwards! 🚀

For more information, visit our website:
www.s2m.se

We're excited to announce that S2Medical AB (publ) has just released its annual report for 2023!

You can now access it on our website: www.s2m.se

Printed copies will also be available at our upcoming annual general meeting on June 7, 2024.

Shareholders and interested parties can request a printed copy by emailing [email protected].

Stay updated with our latest financial updates and milestones!